X

Trial Profile

Multicenter Study of Patients With Hypertension Resistant to Patient Identification and Standardization of Therapeutic

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clonidine (Primary) ; Spironolactone (Primary) ; ACE inhibitors; Amlodipine; Angiotensin receptor antagonists; Chlortalidone
Indications Resistant hypertension
Focus Biomarker; Therapeutic Use
Acronyms ReHOT

Most Recent Events

07 Jun 2013 Biomarkers information updated
06 Jun 2013 Planned End Date changed from 1 Dec 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
03 Aug 2012 Trial phase changed from III to IV as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com